ECT2

Across TCGA pan-cancer cohorts, ECT2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ECT2 data layer compared with 28 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ECT2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ECT2 expression acts as an unfavorable survival marker.

COAD, LUAD, and PDAC are the cancer types where ECT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Tertile	All	0.855	1.000	.017	48	view →
LUAD	OS	Quartile	II,III,IV	0.261	0.871	.006	10	view →
PDAC	OS	Median	All	0.723	0.929	.029	3	view →
HNSC	DFS	Median	IV	0.572	0.798	.031	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ECT2–COAD (DFS)

Open the COAD breakdown →